Drug and biologics makers are facing an FDA data crackdown with inspectors digging deeper into data integrity issues amid rising concerns over Forms 483 and warning letters. Former Deputy Director of...
(PRWeb February 26, 2018)
Read the full story at http://www.prweb.com/releases/2018/02/prweb15245573.htm